Monoclonal antibody · Antagonist of leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) · developed by NextCure
NC525 is a humanized IgG1 kappa monoclonal antibody that binds LAIR1, an immune inhibitory checkpoint receptor, and inhibits LAIR1-mediated survival signaling. It also induces antibody-dependent cellular cytotoxicity and phagocytosis. It is studied in relapsed or refractory acute myeloid leukemia, chronic myelomonocytic leukemia and myelodysplastic syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05787496 | Phase 1 | Relapsed or Refractory Acute Myeloid Leukemia | Terminated | NXTC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic LeukemiaRelapsed or Refractory Myelodysplastic Syndrome
Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.
See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NXTC catalysts and pipeline →